For centuries, humanity has fought infectious diseases by reacting to outbreaks after they emerge. From influenza to COVID-19, scientists have often raced against time to develop vaccines while viruses spread across populations.
Now, researchers believe artificial intelligence could fundamentally change that equation.
In what scientists describe as a major breakthrough in vaccine development, researchers at the University of Cambridge have successfully created and tested in humans a new type of vaccine whose critical component was designed entirely by artificial intelligence. The development raises hopes that future vaccines could protect against entire families of viruses before they trigger global health emergencies.
The research represents a significant shift from conventional vaccine design, which typically targets viruses already circulating among humans. Instead, scientists are attempting to anticipate future threats by training AI systems to identify common features shared across multiple viruses, including those that have yet to infect people.
At the heart of the project is a bold ambition: creating vaccines that remain effective even as viruses evolve, mutate and cross from animals to humans.
“This is about making vaccines that protect us, not just from today’s viruses, but protect us from what can cause the next outbreak or disease,” said Jonathan Heeney, who leads the research team.
For public health experts, the implications are enormous.
The COVID-19 pandemic exposed both the power and limitations of modern vaccine technology. While scientists developed effective vaccines in record time, the virus continued to mutate, forcing governments and pharmaceutical companies to update vaccines repeatedly to keep pace with new variants.
Researchers say AI could help reverse that cycle. Rather than chasing viruses after they emerge, artificial intelligence is being used to predict how entire groups of viruses behave and identify biological targets that remain relatively unchanged across multiple strains. The result is what scientists call a “super-antigen”, a vaccine component designed to train the immune system to recognise a broad spectrum of related viruses.
The first target was the coronavirus family, which includes SARS-CoV-2, the virus responsible for COVID-19, as well as numerous animal coronaviruses that scientists fear could trigger future outbreaks.
Using genetic information gathered through global surveillance programmes, researchers fed vast amounts of viral data into an AI system. The technology analysed similarities across numerous coronavirus strains and generated a vaccine antigen capable of providing broad protection against existing and potentially emerging variants.
The achievement marks what researchers believe is the first time an AI-designed vaccine antigen has advanced to human testing.
For many scientists, however, the breakthrough extends beyond coronavirus protection. It offers a glimpse into a future where artificial intelligence becomes a central tool in pandemic prevention.
The initial trial involving 39 volunteers focused primarily on safety. While early findings published in the Journal of Infection described the immune response as modest, researchers say the results are encouraging enough to justify larger studies involving approximately 200 participants.
Experts not involved in the vaccine’s design have also expressed optimism.
According to Saul Faust, who participated in some of the clinical trials, AI-driven vaccine design could prove particularly valuable in combating viruses that evolve rapidly.
“What is really interesting is that the technology is an awful lot better at designing vaccines for potential pandemics when viruses are changing,” he said.
The timing of the breakthrough is significant. Public health agencies worldwide are increasingly concerned about the growing risk of zoonotic diseases, viruses that jump from animals to humans. Scientists estimate that more than 70 per cent of emerging infectious diseases originate in animals, with bats, birds and livestock often serving as reservoirs for dangerous pathogens.
The emergence of COVID-19, Ebola, SARS and avian influenza has reinforced fears that the next pandemic may already be circulating silently in animal populations.
Recognising this threat, the Cambridge team is already expanding its work beyond coronaviruses. Researchers are developing universal influenza vaccines that could eliminate the need for annual flu shots, as well as vaccines targeting H5N1 bird flu, a virus that continues to devastate bird populations and remains under close global surveillance due to its pandemic potential.
The development also highlights the growing role of artificial intelligence in medicine. While AI is already being used to accelerate drug discovery, analyse medical images and support disease diagnosis, vaccine design represents one of its most ambitious applications yet.
Supporters argue that AI can process vast amounts of biological data in ways impossible for human researchers alone, dramatically reducing the time needed to identify promising vaccine targets. In a world where pandemics can spread across continents within weeks, such speed could prove invaluable.
Yet experts caution that the technology remains in its infancy. Larger clinical trials are needed to determine whether AI-designed vaccines can provide the broad, long-lasting protection researchers hope to achieve.
Even so, the breakthrough signals a future in which humanity may no longer be forced to wait for the next pandemic before preparing for it.
